Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 123

1.

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.

Tutuka CSA, Andrews MC, Mariadason JM, Ioannidis P, Hudson C, Cebon J, Behren A.

Mol Cancer. 2017 Jun 28;16(1):112. doi: 10.1186/s12943-017-0684-x.

2.

Concurrent <i>BRAF</i> and <i>PTEN</i> mutations in melanoma of unknown origin presenting as a breast mass.

Agosto-Arroyo E, Rosa M, Chau A, Khazai L.

SAGE Open Med Case Rep. 2017 May 31;5:2050313X17711064. doi: 10.1177/2050313X17711064. eCollection 2017.

3.

The clinical features, treatment, and prognosis of primary mediastinal malignant melanoma: A case report.

Li Z, Jia H, Zhang B, Zhang Y, Li H, Song P.

Medicine (Baltimore). 2017 Apr;96(17):e6436. doi: 10.1097/MD.0000000000006436.

4.

<i>BRAF</i><sup>V600</sup> mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study.

Cohn AL, Day BM, Abhyankar S, McKenna E, Riehl T, Puzanov I.

Onco Targets Ther. 2017 Feb 17;10:965-971. doi: 10.2147/OTT.S120440. eCollection 2017.

5.

Genomic analysis and clinical management of adolescent cutaneous melanoma.

Rabbie R, Rashid M, Arance AM, Sánchez M, Tell-Marti G, Potrony M, Conill C, van Doorn R, Dentro S, Gruis NA, Corrie P, Iyer V, Robles-Espinoza CD, Puig-Butille JA, Puig S, Adams DJ.

Pigment Cell Melanoma Res. 2017 May;30(3):307-316. doi: 10.1111/pcmr.12574. Epub 2017 Apr 19.

6.

Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.

Schaefer T, Satzger I, Gutzmer R.

Medicine (Baltimore). 2017 Jan;96(1):e5753. doi: 10.1097/MD.0000000000005753.

7.

Fragment Length of Circulating Tumor DNA.

Underhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, Baker DN, Gligorich KM, Rostomily RC, Bronner MP, Shendure J.

PLoS Genet. 2016 Jul 18;12(7):e1006162. doi: 10.1371/journal.pgen.1006162. eCollection 2016 Jul.

8.

Profiling networks of distinct immune-cells in tumors.

Clancy T, Hovig E.

BMC Bioinformatics. 2016 Jul 4;17(1):263. doi: 10.1186/s12859-016-1141-3.

9.

Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.

Behling F, Barrantes-Freer A, Skardelly M, Nieser M, Christians A, Stockhammer F, Rohde V, Tatagiba M, Hartmann C, Stadelmann C, Schittenhelm J.

Diagn Pathol. 2016 Jun 27;11(1):55. doi: 10.1186/s13000-016-0506-2.

10.

BRAF-Directed Therapy in Metastatic Colorectal Cancer.

Korphaisarn K, Kopetz S.

Cancer J. 2016 May-Jun;22(3):175-8. doi: 10.1097/PPO.0000000000000189. Review.

11.

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.

Casadevall D, Vidal J, Gallardo F, Zuccarino F, Arumí-Uría M, Dalmases A, Bellosillo B, Montagut C.

J Med Case Rep. 2016 Jun 2;10(1):158. doi: 10.1186/s13256-016-0953-0.

12.

NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand.

Jones AM, Ferguson P, Gardner J, Rooker S, Sutton T, Ahn A, Chatterjee A, Bickley VM, Sarwar M, Emanuel P, Kenwright D, Shepherd PR, Eccles MR.

Oncotarget. 2016 Jul 5;7(27):41017-41030. doi: 10.18632/oncotarget.9351.

13.

BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.

Paoluzzi L, Hanniford D, Sokolova E, Osman I, Darvishian F, Wang J, Bradner JE, Hernando E.

Cancer Med. 2016 Jun;5(6):1183-93. doi: 10.1002/cam4.667. Epub 2016 May 11.

14.

Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma.

Harlé A, Salleron J, Franczak C, Dubois C, Filhine-Tressarieu P, Leroux A, Merlin JL.

PLoS One. 2016 Apr 25;11(4):e0153576. doi: 10.1371/journal.pone.0153576. eCollection 2016.

15.

The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.

Pinheiro C, Miranda-Gonçalves V, Longatto-Filho A, Vicente AL, Berardinelli GN, Scapulatempo-Neto C, Costa RF, Viana CR, Reis RM, Baltazar F, Vazquez VL.

Cell Cycle. 2016 Jun 2;15(11):1462-70. doi: 10.1080/15384101.2016.1175258. Epub 2016 Apr 22.

16.

A somatic reference standard for cancer genome sequencing.

Craig DW, Nasser S, Corbett R, Chan SK, Murray L, Legendre C, Tembe W, Adkins J, Kim N, Wong S, Baker A, Enriquez D, Pond S, Pleasance E, Mungall AJ, Moore RA, McDaniel T, Ma Y, Jones SJ, Marra MA, Carpten JD, Liang WS.

Sci Rep. 2016 Apr 20;6:24607. doi: 10.1038/srep24607.

17.

Therapeutic implications of melanoma heterogeneity.

Hachey SJ, Boiko AD.

Exp Dermatol. 2016 Jul;25(7):497-500. doi: 10.1111/exd.13002. Epub 2016 May 19.

18.

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, Schrock AB, Morosini D, Ross JS, Miller VA, Stephens PJ, Ou SH, Ali SM.

Cancer Discov. 2016 Jun;6(6):594-600. doi: 10.1158/2159-8290.CD-15-1192. Epub 2016 Apr 5.

19.

Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.

Yoshida A, Lee EK, Diehl JA.

Cancer Res. 2016 May 15;76(10):2990-3002. doi: 10.1158/0008-5472.CAN-15-2931. Epub 2016 Mar 17.

20.

Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines.

Dorris ER, Blackshields G, Sommerville G, Alhashemi M, Dias A, McEneaney V, Smyth P, O'Leary JJ, Sheils O.

Cancer Biol Ther. 2016 May 3;17(5):526-42. doi: 10.1080/15384047.2016.1139230. Epub 2016 Feb 1.

Supplemental Content

Loading ...
Support Center